Immunovant, Inc. (IMVT) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
IMVT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Immunovant, Inc. (IMVT) trades at a price-to-earnings ratio of -10.2x, with a stock price of $27.84 and trailing twelve-month earnings per share of $-2.56.
Compared to the Healthcare sector median P/E of 22.2x, IMVT trades at a 146% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.
Relative to the broader market, IMVT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IMVT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IMVT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.7 | 1.12 | -25% | |
| $25B | 20.5 | 1.07Best | +13% | |
| $4B | 16.4Lowest | - | +468%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See IMVT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMVT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMVT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIMVT — Frequently Asked Questions
Quick answers to the most common questions about buying IMVT stock.
Is IMVT stock overvalued or undervalued?
IMVT current P/E: -10.2x. 5-year average P/E: N/A. Percentile: N/A.
How does IMVT's valuation compare to peers?
Immunovant, Inc. P/E of -10.2x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is IMVT's PEG ratio?
IMVT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.